Google
Apple
English (UK)
English (Canada)
Deutsch (Deutschland)
Deutsch (Schweiz)
Español
Français (France)
Italiano
Nederlands (Nederland)
Nederlands (België)
CHINOOK THERAPEUTICS, INC. |
Delayed
Other stock markets
|
|
5-day change | 1st Jan Change | |
| 40.39 USD | +0.22% | +0.25% | +54.16% | |
| Aug. 11 | Chinook Therapeutics, Inc. Announces Board Cessations | CI |
| Aug. 11 | Novartis Says it Completed Chinook Therapeutics Acquisition | MT |
Chinook Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on discovering, developing and commercializing precision medicines for kidney diseases. Its lead product candidate is atrasentan, a potent and selective endothelin A receptor (ET A receptor), antagonist that is developing for the treatment of proteinuric glomerular diseases. Atrasentan is in Phase III trials for the treatment of IgA nephropathy (IgAN) and proteinuric glomerular diseases. Its second product candidate, BION-1301, is an anti-APRIL monoclonal antibody also in Phase II development for patients with IgAN. Its third product candidate, CHK-336, is an oral small molecule lactate dehydrogenase (LDHA), inhibitor for the treatment of primary and idiopathic hyperoxaluria that is in a Phase I clinical trial in healthy volunteers. In addition, the Company is also conducting research programs in several other rare, severe chronic kidney diseases.
Calendar
2024-04-02
- Q4 2023 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| +54.16% | 2 900 M $ | |
| +22.16% | 90 447 M $ | |
| +12.98% | 85 991 M $ | |
| +1.98% | 34 975 M $ | |
| +15.91% | 26 060 M $ | |
| -33.82% | 23 593 M $ | |
| -27.41% | 20 576 M $ | |
| -15.82% | 19 064 M $ | |
| -3.47% | 11 156 M $ | |
| +21.74% | 10 875 M $ |
- Stock
- Equities
- Stock Chinook Therapeutics, Inc. - Nasdaq
- News Chinook Therapeutics, Inc.
- Wedbush Downgrades Chinook Therapeutics to Neutral From Outperform as Sale to Novartis Draws Closer; Keeps $42 Price Target